elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Pricing
Log in
Sign up
Home
/
Subjects
/
radioligand therapy
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Application
keyword
radioligand therapy
RIS
0.002
(Research Intensity Score)
Papers
269
Top papers
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
2021 · 2750 citations
Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study
2024 · 195 citations
Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials
2023 · 98 citations
A Meta-Analysis and Meta-Regression of the Efficacy, Toxicity, and Quality of Life Outcomes Following Prostate-Specific Membrane Antigen Radioligand Therapy Utilising Lutetium-177 and Actinium-225 in Metastatic Prostate Cancer
2024 · 35 citations
[ 68 Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [ 177 Lu]Lu-PSMA-617 in patients with mCRPC: A VISION substudy.
2022 · 82 citations
Targeted Alpha Therapy: Exploring the Clinical Insights into [225Ac]Ac-PSMA and Its Relevance Compared with [177Lu]Lu-PSMA in Advanced Prostate Cancer Management
2025 · 12 citations
Therapeutic Applications of Fibroblast Activation Protein (FAP)-Binding Radiopharmaceuticals: Review of Opportunities and Challenges
2025 · 9 citations
Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT
2024 · 21 citations
Efficacy and safety of rechallenge therapy with [177Lu]Lu-PSMA in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis
2025 · 9 citations
Newest papers
PSMA-Based Radiopharmaceuticals in Prostate Cancer Theranostics: Imaging, Clinical Advances, and Future Directions
2026 · 5 citations
[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study
2026 · 2 citations
Estimation and Correction of the Partial Volume Effect Using Personalized Phantoms of Lymph Node Metastases in Lutetium 177 SPECT/CT Dosimetry
2026 · 1 citations
Optimizing FAPI homodimers for theranostic applications: The impact of the linker design in DOTAGA.Glu2.(FAPI)2 and DOTAGA.PEG2.Glu.(FAPI)2
2026
Optimizing FAPI homodimers for theranostic applications: The impact of the linker design in DOTAGA.Glu2.(FAPI)2 and DOTAGA.PEG2.Glu.(FAPI)2.
2026
Radioligand therapy with lutetium-177-PSMA in metastatic castration-resistant prostate cancer with bone involvement: a comprehensive review
2026
Exploring the 89Zr/177Lu Theranostic Pairing with an Extracellular Matrix–Targeted Radiopharmaceutical against Triple-Negative Breast Cancer
2026 · 2 citations
The Past, Present, and Future of PSMA-Targeted Therapies in Prostate Cancer
2026
Newly diagnosed high-risk localized prostate cancer after multiple [177Lu]Lu-PSMA radioligand therapy in the context of metastatic parotid carcinoma: a case report
2026
Browse all papers →
radioligand therapy's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
radioligand therapy's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link